Skip to main content
Year archive

Alvotech Holdings S.A — 2023 filings

All 226 regulatory filings released by Alvotech Holdings S.A (ALVO) in 2023, sourced directly from the official regulator.

226 Filings
2023 Period
2023 filings (226)
Filing Released Lang
FORM 6-K/A
Regulatory Filings
2023-11-30 English
FORM 6-K
Regulatory Filings
2023-11-29 English
FORM 6-K
Regulatory Filings
2023-11-29 English
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Regulatory Filings
2023-11-29 Icelandic
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Regulatory Filings
2023-11-29 English
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Interim / Quarterly Report 9M 2023
2023-11-28 English
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Interim / Quarterly Report 9M 2023
2023-11-28 English
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
Report Publication Announcement
2023-11-21 Icelandic
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
Report Publication Announcement
2023-11-21 English
FORM 6-K
Regulatory Filings
2023-11-15 English
Alvotech Accepts Offer to Sell its Subsidiary in Hannover, Germany
M&A Activity
2023-11-15 English
FORM 6-K
Regulatory Filings
2023-11-14 English
Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara
Regulatory Filings
2023-11-14 Icelandic
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Regulatory Filings
2023-11-14 English
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Regulatory Filings
2023-11-14 Icelandic
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Regulatory Filings
2023-11-14 English
FORM 6-K
Regulatory Filings
2023-11-13 English
STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to Stelara
Legal Proceedings Report
2023-11-10 Icelandic
STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to Stelara
Regulatory Filings
2023-11-10 English
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
Regulatory Filings
2023-11-07 Icelandic
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
Regulatory Filings
2023-11-07 English
Regulatory Filings 2023
Regulatory Filings
2023-10-31 English
Regulatory Filings 2023
Regulatory Filings
2023-10-27 English
Regulatory Filings 2023
Regulatory Filings
2023-10-26 English
F-3 Registration Statement 2023-10-20.pdf
Transaction in Own Shares
2023-10-20 English
F-3 skráningareyðublað lagt inn til Verðbréfaeftirlits Bandaríkjanna
Report Publication Announcement
2023-10-20 Icelandic
F-3 Registration Statement 2023-10-20.pdf
Transaction in Own Shares
2023-10-20 English
Form F-3 Filed With the United States Securities and Exchange Commission
Regulatory Filings
2023-10-20 English
Form F-3 Filed With the United States Securities and Exchange Commission
Regulatory Filings
2023-10-20 English
Form F-3 Filed With the United States Securities and Exchange Commission
Regulatory Filings
2023-10-20 English
Regulatory Filings 2023
Regulatory Filings
2023-10-20 English
FORM 6-K
Regulatory Filings
2023-10-12 English
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Regulatory Filings
2023-10-12 Icelandic
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Regulatory Filings
2023-10-12 English
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
Regulatory Filings
2023-10-05 Icelandic
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
M&A Activity
2023-10-05 English
FORM 6-K
Regulatory Filings
2023-10-03 English
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
M&A Activity
2023-10-03 Icelandic
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
M&A Activity
2023-10-03 English
FORM 6-K
Regulatory Filings
2023-09-25 English
Markaðsleyfi veitt í Japan fyrir AVT04 (ustekinumab), líftæknilyfjahliðstæðu Alvotech við Stelara®
Regulatory Filings
2023-09-25 Icelandic
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Regulatory Filings
2023-09-25 English
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Regulatory Filings
2023-09-25 Icelandic
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Regulatory Filings
2023-09-25 English
Regulatory Filings 2023
Regulatory Filings
2023-09-21 English
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
Regulatory Filings
2023-09-20 Icelandic
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
Regulatory Filings
2023-09-20 English
Alvotech 2023 Q2 Unaudited Consolidated Financial Statements (2)
Interim / Quarterly Report H1 2023
2023-09-12 English
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Report Publication Announcement
2023-09-11 Icelandic
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Report Publication Announcement
2023-09-11 English
Regulatory Filings 2023
Regulatory Filings
2023-09-07 English
Regulatory Filings 2023
Regulatory Filings
2023-09-05 English
Alvotech Announces Changes to the Leadership Team
Board/Management Information
2023-09-05 Icelandic
Alvotech Announces Changes to the Leadership Team
Board/Management Information
2023-09-05 English
Regulatory Filings 2023
Regulatory Filings
2023-08-31 English
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Interim / Quarterly Report H1 2023
2023-08-30 English
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Management Reports
2023-08-30 English
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Management Reports
2023-08-30 English
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Interim / Quarterly Report H1 2023
2023-08-30 English
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Regulatory Filings
2023-08-29 Icelandic
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Regulatory Filings
2023-08-29 English
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
Report Publication Announcement
2023-08-22 Icelandic
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
Report Publication Announcement
2023-08-22 English
Transactions of Managers and Closely Associated Persons
Director's Dealing
2023-08-18 English
Transactions of Managers and Closely Associated Persons
Director's Dealing
2023-08-18 English
Managers Transaction-CSSF Form - ATP Holdings ehf 20230816
Director's Dealing
2023-08-18 English
Regulatory Filings 2023
Regulatory Filings
2023-08-01 English
Alvotech Completes $100 Million Convertible Bond Private Placement
Capital/Financing Update
2023-07-31 Icelandic
Alvotech Completes $100 Million Convertible Bond Private Placement
Capital/Financing Update
2023-07-31 English
Regulatory Filings 2023
Regulatory Filings
2023-07-24 English
Regulatory Filings 2023
Regulatory Filings
2023-07-24 English
Regulatory Filings 2023
Regulatory Filings
2023-07-24 English
Alvotech selur breytanleg skuldabréf í lokuðu útboði
Capital/Financing Update
2023-07-24 Icelandic
Alvotech Announces Private Placement of Convertible Bonds to Qualified Investors in an Overseas Directed Offering
Capital/Financing Update
2023-07-24 English
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Regulatory Filings
2023-07-24 Icelandic
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Capital/Financing Update
2023-07-24 English
Regulatory Filings 2023
Regulatory Filings
2023-07-24 English
Regulatory Filings 2023
Regulatory Filings
2023-07-21 English
Regulatory Filings 2023
Regulatory Filings
2023-07-20 English
Regulatory Filings 2023
Regulatory Filings
2023-07-20 English
Forms filed with the US Securities and Exchange Commission on July 14, 2023
Capital/Financing Update
2023-07-17 English
Regulatory Filings 2023
Regulatory Filings
2023-07-14 English
Regulatory Filings 2023
Regulatory Filings
2023-07-14 English
Filing of previously disclosed partnership agreements
M&A Activity
2023-07-12 English
Regulatory Filings 2023
Regulatory Filings
2023-07-12 English
424B3
Regulatory Filings
2023-06-29 English
6-K
Regulatory Filings
2023-06-29 English
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Regulatory Filings
2023-06-28 Icelandic
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Regulatory Filings
2023-06-28 English
Transactions of Managers and Closely Associated Persons
Director's Dealing
2023-06-22 English
Managers' Transaction Notifications - Linda McGoldrick(20230621)
Director's Dealing
2023-06-22 English
Managers' Transaction Notifications - Lisa Graver(20230621)
Director's Dealing
2023-06-22 English
Managers' Transaction Notifications - Ann Merchant(20230621)
Director's Dealing
2023-06-22 English
Managers' Transaction Notifications - Richard Davies (20230621)
Director's Dealing
2023-06-22 English
6-K
Regulatory Filings
2023-06-13 English
Alvotech og Teva ná samningi um upphafsdag sölu á AVT04, líftæknilyfjahliðstæðu við Stelara®, í Bandaríkjunum
Regulatory Filings
2023-06-12 Icelandic
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Regulatory Filings
2023-06-12 English
424B3
Regulatory Filings
2023-06-06 English
6-K
Regulatory Filings
2023-06-06 English
Alvotech Minutes of the Annual General Meeting 2023-06-06.pdf
Declaration of Voting Results & Voting Rights Announcements
2023-06-06 French
Alvotech Remuneration Policy 2023-06-06.pdf
Remuneration Information
2023-06-06 English
Niðurstaða aðalfundar
Declaration of Voting Results & Voting Rights Announcements
2023-06-06 Icelandic
Alvotech Minutes of the Annual General Meeting 2023-06-06.pdf
Declaration of Voting Results & Voting Rights Announcements
2023-06-06 French
Alvotech Remuneration Policy 2023-06-06.pdf
Remuneration Information
2023-06-06 English
Main Results of Annual and Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements
2023-06-06 English
Úthlutun kauprétta
Share Issue/Capital Change
2023-06-06 Icelandic
Granting of Stock Options
Share Issue/Capital Change
2023-06-06 English
Alvotech to Participate in Jefferies Healthcare Conference
Regulatory Filings
2023-05-31 Icelandic
Alvotech to Participate in Jefferies Healthcare Conference
Regulatory Filings
2023-05-31 English
Transactions of Managers and Closely Associated Persons
Director's Dealing
2023-05-26 English
ATP Holdings ehf - Managers Transaction Notification (20230524)
Director's Dealing
2023-05-24 English
424B3
Regulatory Filings
2023-05-24 English
6-K
Regulatory Filings
2023-05-24 English
Filing of Information Related to Press Release on Agreement Between Alvotech and Advanz Pharma
Regulatory Filings
2023-05-24 English
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
Regulatory Filings
2023-05-24 English
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
M&A Activity
2023-05-24 Icelandic
6-K
Regulatory Filings
2023-05-19 English
Alvotech 2023 Q1 Financial Statements.xlsx
Interim / Quarterly Report
2023-05-19 English
Alvotech 2023 Q1 Earnings Presentation.pdf
Investor Presentation
2023-05-19 English
Alvotech birtir uppgjör fyrir fyrstu þrjá mánuði ársins 2023 og kynnir nýjustu áfanga í rekstri félagsins
Earnings Release Q1 2023
2023-05-19 Icelandic
Alvotech 2023 Q1 Financial Statements.xlsx
Interim / Quarterly Report
2023-05-19 English
Alvotech 2023 Q1 Earnings Presentation.pdf
Investor Presentation
2023-05-19 English
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Earnings Release Q1 2023
2023-05-19 English
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
Regulatory Filings
2023-05-17 Icelandic
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
Environmental & Social Information
2023-05-17 English
Alvotech Issues Annual Equality Report Covering 2022
Report Publication Announcement
2023-05-15 Icelandic
Alvotech Issues Annual Equality Report Covering 2022
Environmental & Social Information
2023-05-15 English
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
Regulatory Filings
2023-05-10 Icelandic
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
M&A Activity
2023-05-10 English
6-K
Regulatory Filings
2023-05-05 English
Alvotech S.A. Annual General Meeting to be held June 6, 2023
AGM Information
2023-05-05 English
Alvotech S.A. Annual General Meeting to be held June 6, 2023
AGM Information
2023-05-05 English
56e766be-c984-424f-9b38-35e01b4c6f81
Audit Report / Information FY 2022
2023-05-04 English
6-K
Regulatory Filings
2023-05-04 English
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Legal Proceedings Report
2023-05-04 Icelandic
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Legal Proceedings Report
2023-05-04 English
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
Report Publication Announcement
2023-05-03 Icelandic
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
Report Publication Announcement
2023-05-03 English
6-K
Regulatory Filings
2023-04-20 English
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
Board/Management Information
2023-04-19 Icelandic
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
Board/Management Information
2023-04-19 English
6-K
Regulatory Filings
2023-04-18 English
FDA Status Update
Legal Proceedings Report
2023-04-17 Icelandic
FDA Status Update
Legal Proceedings Report
2023-04-17 English
424B3
Regulatory Filings
2023-04-14 English
6-K
Regulatory Filings
2023-04-14 English
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi í Bandaríkjunum fyrir AVT02
Regulatory Filings
2023-04-14 Icelandic
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
Regulatory Filings
2023-04-14 English
Managers Transaction-CSSF Form - ATP Holdings ehf 20230411.pdf
Director's Dealing
2023-04-13 English
Managers Transaction-CSSF Form - ATP Holdings ehf 20230405.pdf
Director's Dealing
2023-04-13 English
Transactions of managers and closely associated persons
Director's Dealing
2023-04-13 English
Managers Transaction-CSSF Form - (SHINHAN) ATP Holdings ehf 20230405
Director's Dealing
2023-04-13 English
Managers Transaction-CSSF Form - (MITSUI) ATP Holdings ehf 20230411
Director's Dealing
2023-04-13 English
pdf6297842525443063744
Major Shareholding Notification
2023-04-06 English
Annex B - Total Voting Rights - Alvotech
Declaration of Voting Results & Voting Rights Announcements
2023-03-31 English
Alvotech Announces Increase in Number of Own Shares (1)
Share Issue/Capital Change
2023-03-29 English
6-K
Regulatory Filings
2023-03-28 English
Alvotech Announces Increase in Number of Own Shares
Share Issue/Capital Change
2023-03-28 Icelandic
Alvotech Announces Increase in Number of Own Shares
Share Issue/Capital Change
2023-03-28 English
Alvotech birtir nýjar upplýsingar um sjálfbærni og samfélagslega ábyrgð
Environmental & Social Information
2023-03-28 Icelandic
Alvotech Provides Update on Corporate Sustainability Framework
Environmental & Social Information
2023-03-28 English
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
Regulatory Filings
2023-03-17 Icelandic
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
Regulatory Filings
2023-03-17 English
Regulatory Filings 2023
Regulatory Filings
2023-03-17 English
pdf9831376877052378812 (4)
Major Shareholding Notification
2023-03-14 English
POS AM
Regulatory Filings
2023-03-13 English
222100DCZBOWV5DZ8372-2022-12-31-en
Annual Report FY 2022
2023-03-10 English
20-F
Annual Report FY 2022
2023-03-01 English
alvotech-reports-financial-results-for-full-year
Earnings Release FY 2022
2023-03-01 English
6-K
Regulatory Filings
2023-03-01 English
Alvotech birtir uppgjör fyrir árið 2022 og kynnir nýjustu áfanga í rekstri félagsins
Earnings Release FY 2022
2023-03-01 Icelandic
222100DCZBOWV5DZ8372-2022-12-31-en.zip
Annual Report FY 2022
2023-03-01 English
Alvotech Consolidated Financial Statements FY 2022.pdf
Annual Report FY 2022
2023-03-01 English
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
Earnings Release FY 2022
2023-03-01 English
Alvotech Annex B Total Voting Rights (20230228)
Share Issue/Capital Change
2023-02-28 English
Alvotech birtir uppgjör ársins 2022 þann 1. mars nk. og heldur kynningarfund 2. mars nk.
Report Publication Announcement
2023-02-28 Icelandic
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
Report Publication Announcement
2023-02-28 English
SC 13G
Major Shareholding Notification
2023-02-14 English
Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market
Capital/Financing Update
2023-02-14 Icelandic
Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market
Regulatory Filings
2023-02-14 English
424B3
Regulatory Filings
2023-02-10 English
424B3
Regulatory Filings
2023-02-10 English
6-K
Regulatory Filings
2023-02-10 English
Settlement of Alvotech Private Share Placement Completed
Share Issue/Capital Change
2023-02-10 Icelandic
Settlement of Alvotech Private Share Placement Completed
Share Issue/Capital Change
2023-02-10 English
424B3
Regulatory Filings
2023-02-09 English
424B3
Regulatory Filings
2023-02-09 English
6-K
Regulatory Filings
2023-02-09 English
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Regulatory Filings
2023-02-09 Icelandic
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Regulatory Filings
2023-02-09 English
6-K
Regulatory Filings
2023-02-07 English
6-K
Regulatory Filings
2023-02-07 English
Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)
M&A Activity
2023-02-06 Icelandic
Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)
Regulatory Filings
2023-02-06 English
Alvotech - ISK-Bond Instrument ALVCVB251220 Listing.pdf
Capital/Financing Update
2023-02-05 English
Birting skráningarskjals vegna breytilegra skuldabréfa ALVCVB251220
Capital/Financing Update
2023-02-05 Icelandic
Birting skráningarskjals vegna breytilegra skuldabréfa ALVCVB251220
Regulatory Filings
2023-02-05 English
6-K
Regulatory Filings
2023-01-24 English
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Regulatory Filings
2023-01-24 Icelandic
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Regulatory Filings
2023-01-24 English
424B3
Regulatory Filings
2023-01-23 English
424B3
Regulatory Filings
2023-01-23 English
6-K
Regulatory Filings
2023-01-23 English
Alvotech selur hlutabréf fyrir 19,5 milljarða króna í lokuðu útboði til innlendra fagfjárfesta
Capital/Financing Update
2023-01-23 Icelandic
Alvotech Completes $137 Million Private Share Placement
Capital/Financing Update
2023-01-23 English
6-K
Regulatory Filings
2023-01-20 English
Alvotech initiates proposed private share placement to professional clients and eligible counterparties in Iceland
Share Issue/Capital Change
2023-01-20 Icelandic
Alvotech initiates proposed private share placement to professional clients and eligible counterparties in Iceland
Capital/Financing Update
2023-01-20 English
Alvogen Lux Holdings Sarl - Corrective CSSF filing
Major Shareholding Notification
2023-01-19 English
6-K
Regulatory Filings
2023-01-17 English
FDA Inspection of Manufacturing Facility
Regulatory Filings
2023-01-17 Icelandic
FDA Inspection of Manufacturing Facility
Legal Proceedings Report
2023-01-17 English
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
Regulatory Filings
2023-01-13 Icelandic
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
M&A Activity
2023-01-13 English
424B3
Regulatory Filings
2023-01-11 English
424B3
Regulatory Filings
2023-01-11 English
6-K
Regulatory Filings
2023-01-11 English
Aztiq Major Holdings Notification
Major Shareholding Notification
2023-01-11 English
Alvotech Manco Major Holdings Notification
Major Shareholding Notification
2023-01-11 English
Alvotech hefur rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria®
Regulatory Filings
2023-01-11 Icelandic
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Regulatory Filings
2023-01-11 English
424B3
Regulatory Filings
2023-01-06 English
424B3
Regulatory Filings
2023-01-06 English
6-K
Regulatory Filings
2023-01-06 English
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Legal Proceedings Report
2023-01-06 Icelandic
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Regulatory Filings
2023-01-06 English